Batra Atul, Kashyap Seema, Singh Lata, Bakhshi Sameer
Departments of Medical Oncology, New Delhi, India; Dr. B.R.A. Institute Rotary Cancer Hospital, New Delhi, India; All India Institute of Medical Sciences, New Delhi, India.
Departments of Ocular Pathology, New Delhi, India; All India Institute of Medical Sciences, New Delhi, India.
Ocul Oncol Pathol. 2015 Dec;2(2):86-90. doi: 10.1159/000439594. Epub 2015 Sep 24.
Sirtuin1 (Sirt1) is a member of highly conserved proteins and has been implicated as a tumor promoter as well as a tumor suppressor. One of the mechanisms involves deacetylation of retinoblastoma protein, thereby inhibiting the tumor suppressor function. No study has been reported on the expression of Sirt1 in retinoblastoma.
We assessed the expression of Sirt1 in sections of archived tissue blocks of enucleated and exenterated specimens of retinoblastoma patients by immunohistochemistry. The histopathological features were reviewed and correlated with the expression of Sirt1. The effect of Sirt1 expression on survival was also assessed.
Retrospective data of 94 patients revealed that the median age at presentation was 36 months, with a male:female ratio of 1.9:1. Fifty-one percent of the patients had International Retinoblastoma Staging System (IRSS) stage 1 disease. Of the 94 sections, 89 (95%) expressed Sirt1. Forty-eight percent of the specimens showed grade 3 staining (>75% of the cells), and the intensity was 3+ in 53%. No association between Sirt1 expression and any histopathological feature was noted. Further, Sirt1 expression did not affect the overall and progression-free survival.
Sirt1 was expressed in most of the retinoblastoma samples. However, the degree of Sirt1 expression was not associated with any high-risk histopathological feature or survival.
沉默调节蛋白1(Sirt1)是高度保守的蛋白质家族成员之一,被认为既是肿瘤促进因子又是肿瘤抑制因子。其中一种机制涉及视网膜母细胞瘤蛋白的去乙酰化,从而抑制肿瘤抑制功能。目前尚无关于视网膜母细胞瘤中Sirt1表达的研究报道。
我们通过免疫组织化学评估了视网膜母细胞瘤患者眼球摘除和眶内容物剜除标本存档组织块切片中Sirt1的表达。回顾了组织病理学特征并与Sirt1的表达进行关联分析。还评估了Sirt1表达对生存的影响。
94例患者的回顾性数据显示,就诊时的中位年龄为36个月,男女比例为1.9:1。51%的患者患有国际视网膜母细胞瘤分期系统(IRSS)1期疾病。在94个切片中,89个(95%)表达Sirt1。48%的标本显示3级染色(>75%的细胞),53%的标本染色强度为3+。未发现Sirt1表达与任何组织病理学特征之间存在关联。此外,Sirt1表达不影响总生存期和无进展生存期。
大多数视网膜母细胞瘤样本中表达Sirt1。然而,Sirt1的表达程度与任何高危组织病理学特征或生存均无关联。